Adaptimmune Therapeutics PLC · OTC:ADAPY

Adaptimmune Therapeutics — Corporate Update (May 2019)

40 slides from Adaptimmune Therapeutics's corporate update, May 6, 2019

  1. Slide 1: Disclaimer

    Disclaimer This presentation contains “forward-looking statements,” as that term is defined under the Private Securities Litigation Reform Act of 1995 (PSLRA), which statements may be identified by words such as “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “expect” and o

  2. Slide 2: Headlines

    Headlines • Compelling data with ADP-A2M4 in synovial sarcoma – Partial responses in 4 out of 5 synovial sarcoma patients treated with ~10 billion cells – Tumor shrinkage in nearly all assessed synovial sarcoma patients • Initiating SPEARHEAD-1 trial in synovial sarcoma and MRCLS with ADP-A2M4 • Aim

  3. Slide 3: Previous data announcements ADP-A2M4 and ADP-A2M10 at ESMO 2018

    Previous data announcements ADP-A2M4 and ADP-A2M10 at ESMO 2018 • ADP-A2M4 – Cohort 1 (100 million cells) completed – Cohort 2 (1 billion cells) completed – All 6 patients ovarian – Safety profile established in first two cohorts – One patient had 27% reduction, but progressed at Week 12 • ADP-A2M10

  4. Slide 4: Progress since ESMO 2018 with ADP-A2M4

    Progress since ESMO 2018 with ADP-A2M4 Basket trial in nine solid tumors • Synovial sarcoma added to ADP-A2M4 basket trial • Cohort 3 has been completed (5 billion cell dose target) – 1 synovial sarcoma patient – 2 other patients (ovarian and esophageal) • Expansion Phase has recruited 14 patients (

  5. Slide 5: Data from Cohort and Expansion Phase in ADP-A2M4

    Data from Cohort 3 and Expansion Phase in ADP-A2M4 Partial responses in 4 out of 5 synovial sarcoma patients treated with ~10 billion cells • Synovial sarcoma: – 10 patients treated – 8 – 6 – 4 scanned to date showed tumor shrinkage PRs out of 5 patients treated › 3 confirmed, one unconfirmed with ~

  6. Slide 6: Progress since ESMO 2018 with ADP-A2M10

    Progress since ESMO 2018 with ADP-A2M10 Two trials: one triple tumor and one lung cancer study • Cohort 3 (5 billion dose target) completed – 2 SDs, 1 PD in triple tumor • Safety review permitted Expansion Phase for both studies – Treatment with up to 10 billion cells (now up to 15 billion cells) •

  7. Slide 7: ADP-A2AFP Study in hepatocellular carcinoma (HCC)

    ADP-A2AFP Study in hepatocellular carcinoma (HCC) • Cohort 1 (100 million cells) – Tumor necrosis observed in 1 patient – Decreased serum AFP observed Cohort 2 (1 billion cells) with first patient – Transient decrease in serum AFP – Tumor shrinkage at first scan – Cohort continues to recruit • • Coh

  8. Slide 8: Next steps for ADP-A2M4 and ADP-A2M10

    Next steps for ADP-A2M4 and ADP-A2M10 Two new studies to start and continuing ongoing trials • ADP-A2M4 to start 60-patient SPEARHEAD-1 study in synovial and MRCLS – Aim to launch first TCR T-cell therapy in 2022 – Significant commercial opportunity for Adaptimmune sarcoma • Next generation ADP-A2M4

  9. Slide 9: ADP-A2M4 in synovial sarcoma Topline results

    ADP-A2M4 in synovial sarcoma Topline results 10

  10. Slide 10: Responses in synovial sarcoma ADP-A2M4 Cohort and Expansion

    Responses in synovial sarcoma ADP-A2M4 Cohort 3 and Expansion Tumor shrinkage in nearly all assessed synovial sarcoma patients Patient # (Gender; Age [y]) Baseline SLD (mm) MAGE-A4 expression (%) Peak Persistence a Dose b Best response c Maximum change in SLD (%) d 1+ 2+ 3+ 1 (M, 53) 240 0 0 100 220

  11. Slide 11: ADP-A2M4 synovial sarcoma: Decreases in target lesions

    ADP-A2M4 synovial sarcoma Decreases in target lesions in Cohort 3 and Expansion Change from Baseline in SLD through Progression or Prior to Surgical Resection Maximum Change from Baseline in SLD through Progression or Prior to Surgical Resection 60 40 20 8 7 0 -20 6 5 4 -40 3 2 -60 -80 1 -100 8 7 6

  12. Slide 12: Time on study swimmer plot for ADP-A2M4

    7 8 1 ... 5 Q) .Q E 3 -!: ::I .-!: 2 cc.tl. 4 6 9 X Surgical Resection 10 2 10 12 14 16 18 20 22 2.6 28 0 4 6 8 24 Time from T-Ce/1 lnfu.slon (Weeks) Adaptimmune TRANSFORMING T CEL L THERAPY 13 I Data cut off 30 Apr 2019 0 PartialResponse Unconfirmed PanialResponse· Stable Disease X Progressive Dise

  13. Slide 13: Persistence of ADP-A2M4 SPEAR-T cells in blood

    Persistence of ADP-A2M4 SPEAR-T cells in blood (synovial sarcoma) Response trending with persistence P e r s i s t e n c e i n M A G E - A 4 S a r c o m a p a t i e n t s V e c t o r c o p i e s 1 1 0 6 c P R # 1 1 1 0 5 c P R # 2 c P R # 3 1 1 0 4 u c P R # 4 1 1 0 3 S D # 5 S D # 6 1 1 0 2 S D # 7

  14. Slide 14: Killing activity ex vivo correlates with patient response

    Killing activity ex vivo correlates with patient response ADP-A2M4 SPEAR T-cells isolated from patients (in vitro killing assay) Confirmed PR (Patient #3) Stable disease (Patient #7) Strong killing by patient's cells Poor killing by patient's cells vs. manufactured product (SPEAR T-cells from blood

  15. Slide 15: Patient scans baseline and Week 6

    Baseline Week6 161 Max.=maximum; SLD=sum of lesion(s) diameter(s) Adaptimmune TRANSFORMING T CEL L THERAPY

  16. Slide 16: ADP-A2M4 synovial sarcoma Patient #3 confirmed PR

    m S Baseline Week6 Week 12 171 Max.=maximum; SLD=sum of lesion(s) diameter(s) Adaptimmune TRANSFORMING T CEL L THERAPY ADP-A2M4 synovial sarcoma Patient #3 Confirmed PR with bulky tumor almost completely resolved (-44o/o max. c h ang e in 20 e L D)

  17. Slide 17: SPEARHEAD-1 study starting in 2H 2019 (ADP-A2M4)

    SPEARHEAD-1 study starting in 2H 2019 (ADP-A2M4) Key design elements • • Single-arm, Phase 2 study in more than 20 centers (North America & EU) Sample size of 60 treated subjects with: – Advanced (metastatic or inoperable) synovial sarcoma or MRCLS, who have received prior chemotherapy – HLA-A*02 &

  18. Slide 18: Antitumor activity in other solid tumors with ADP-A2M4

    Antitumor activity solid tumors with ADP-A2M4 in other 19

  19. Slide 19: Summary of ADP-A2M4 in non-sarcoma patients

    Summary of ADP-A2M4 in non-sarcoma patients Tumor shrinkage seen in melanoma (-40%) and ovarian (-9%) * Patient #11 had a -40% maximum change in SLD; best overall response is PD due to new lesions Data cut off 30 Apr 2019 20 Patient # (Gender; Age [y]) Indication Baseline SLD (mm) MAGE-A4 expression

  20. Slide 20: ADP-A2M4 melanoma Patient #11 with high MAGE-A4 expression

    ADP-A2M4 melanoma Patient #11 with high MAGE-A4 expression Decrease in target lesion (-40% max. change in 6 cm SLD) with PD due to new lesions Baseline Week 10 21 * Patient #11 had a -40% maximum change in SLD; best overall response is PD due to new lesions

  21. Slide 21: Antitumor activity with ADP-A2M10

    Antitumor activity ADP-A2M10 with 22

  22. Slide 22: Summary of ADP-A2M10 patients

    Summary of ADP-A2M10 patients Evidence of antitumor activity in two NSCLC patients * Patient received second infusion at Week 16 Data cut off 26 Apr 2019 23 Patient # (Gender; Age [y]) Indication Baseline SLD (mm) MAGE-A10 expression (%) Peak Persistence a Dose b Best response c Maximum change in SL

  23. Slide 23: ADP-A2M10 evidence of antitumor activity in Cohort and Expansion

    ADP-A2M10 - evidence of antitumor activity in Cohort 3 and Two lung patients with decreases in SLD Expansion Change from Baseline in SLD through Progression or Prior to Surgical Resection 7 (H&N) 3 (bladder) 4 (bladder) 6 (H&N) 5 (melanoma) 2 (lung) 1 (lung; 2 infusions) Post-infusion 1 Post-infusio

  24. Slide 24: ADP-A2M10 NSCLC Patient #1 with high MAGE-A10 expression

    t Supraclavicular Lymph Node Right lower lobe Lung Left upper lobe Lung Baseline Nov 2018 -5 months Apr 2019 SA: 2.0 em LA: 3.6 em LA: 1.9 em Adaptimmune TRANSFORMING T CEL L THERAPY 25 I Patient #1 received second infusion at Week 16; post-baseline scans presented are after second infusion les ion

  25. Slide 25: ADP-A2AFP 1st patient at 1 billion cells

    ADP-A2AFP 1st patient at 1 billion cells 26

  26. Slide 26: ADP-A2AFP first patient: strong transient decrease in serum AFP

    ADP-A2AFP first patient treated in Strong transient decrease in serum AFP Cohort 2 with 1 billion cells CTX Cells FDB 27 FGFR4 inh sorafenib aCTLA-4 + aPD-L1

  27. Slide 27: ADP-A2AFP first evidence of tumor shrinkage at first scan

    ADP-A2AFP first patient treated in Cohort 2 with 1 billion cells First evidence of tumor shrinkage at first scan Baseline Week 4 28

  28. Slide 28: Safety across patients

    Safety across patients 29

  29. Slide 29: Safety with SPEAR T-cells

    Safety with SPEAR T-cells Patients treated with ADP-A2M4, ADP-A2M10, and ADP-A2AFP (n=44)* * • Most adverse events are consistent with those typically experienced by cancer patients undergoing cytotoxic chemotherapy or other cancer immunotherapies • There were two reports of CRS ≥ Grade 3 for an inc

  30. Slide 30: Learnings and improving SPEAR T-cells, next steps

    Learnings Improving and next steps SPEAR T-cells 31

  31. Slide 31: Next-generation ADP-A2M4CD8 SPEAR T-cells

    Next-generation ADP-A2M4CD8 SPEAR T-cells SPEAR T-cells targeting MAGE-A4 co-expressing CD8 MAGE-A4+ cells CD4+ SPEAR T-cells (-) Control ADP-A2M4 ADP-A2M4CD8 CD4+ ADP-A2M4CD8 SPEAR T-cell 0h CD4 co-receptor Does not stabilize the TCR target interaction, so no killing – but does bind to DCs CD4+ 143

  32. Slide 32: SURPASS Study (ADP-A2M4CD8) next-gen

    SURPASS Study (ADP-A2M4CD8) next-gen Study start planned for 2H 2019 – IND submitted and initial data in 2020 • • Up to 30 subjects (HLA-A*02 with MAGE-A4+) with: Locally advanced inoperable or metastatic cancer – Same indications as ADP-A2M4 Primary endpoint: safety and tolerability Secondary endpo

  33. Slide 33: Radiation sub-study ADP-A2M4 with MD Anderson Cancer Center

    Radiation sub-study ADP-A2M4 with MD Anderson Cancer Center Improve tumor trafficking • SPEAR T-cells could be more effective if tumor infiltration increased – Preclinical data shows low dose radiation may improve T-cell penetration into tumors* • Radiation sub-study of ADP-A2M4 to be MD Anderson Ca

  34. Slide 34: Lessons learned and next steps in epithelial tumors

    Transform current activity Lessons learned and next steps in epithelial tumors into durable responses 35 Key parameters Adaptimmune approach SURPASS study (ADP-A2M4CD8) Radiation sub-study ADP-A2M4 Dose •Increase doses up to 10 billion cells Lymphodepletion •More intense preconditioning to increase

  35. Slide 35: Our evolving pipeline

    Our evolving pipeline Ongoing and planned studies in multiple solid tumor indications IND APRIL 2019 Melanoma carcinoma Range of other targets and candidates in preclinical stage Significant preclinical progress with allogeneic platform (ASGCT 2019) Aim to launch first TCR T-cell therapy in 2022 36

  36. Slide 36: Looking forward, summary

    Looking forward summary and 37

  37. Slide 37: Looking forward

    Looking forward te • Next targets into clinic 38 2H 2019 •SPEARHEAD-1 study start •SURPASS study start •Radiation study start •Further data from ADP-A2M10 trials •Further data from ADP-A2M4 trials outside sarcoma Beyond 1H 2020 •Allogeneic program data upda •Data from multiple programs 1H 2020 •Dura

  38. Slide 38: Summary

    Summary • Compelling data with ADP-A2M4 in synovial sarcoma – Partial responses in 4 out of 5 synovial sarcoma patients treated with ~10 billion cells – Tumor shrinkage in nearly all assessed synovial sarcoma patients • Initiating SPEARHEAD-1 trial in synovial sarcoma and MRCLS with ADP-A2M4 • Tumor

  39. Slide 39: Adaptimmune Clinical and Business Update

    Adaptimmune TRANSFORMING T CELL THERAPY Clinical and Business Update

  40. Slide 40: Adaptimmune Clinical and Business Update, May 6, 2019

    ) Adaptimmune May 6;2019 Clinical and Business Update

Adaptimmune Therapeutics — Corporate Update (May 2019) on 6ix